NFE2L2 and chronic kidney disease: A phase 2b clinical trial with the NRF2 activator bardoxolone methyl in CKD stages 3b and 4 demonstrated an improvement in estimated glomerular filtration rate (eGFR) but suggested adverse effects, for example, on liver tissue [10].